|Awarded On||November 19, 2015|
|Title||An Adaptive Personalized Clinical Trial using a Patient-Derived Xenograft Strategy to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Michael Wang|
Mantle Cell Lymphoma (MCL) is a type of lymphoma that is rare but presently incurable. Our work led to the FDA approval of ibrutinib, a once-daily, oral drug, to treat patients with relapsed MCL. Although the majority of patients treated with this drug show significantly improved outcomes, most patients become resistant to ibrutinib and experience relapse, with the vast majority of relapsed MCL patients dying within one year. To dramatically improve the cure rate of MCL, novel and pioneering approaches must be taken. To reduce the death rate after ibrutinib relapse, we believe that personalized therapeutic approaches are necessary to achieve this goal; therefore, we are proposing to conduct ...